Several epidemiological studies reported an inverse relationship between plasma highdensity lipoprotein (HDL) cholesterol levels and atherosclerotic cardiovascular disease (ASCVD). However, therapeutic interventions targeted at raising HDL-cholesterol failed to improve cardiovascular outcomes, suggesting that HDL components distinct from cholesterol may account for the anti-atherothrombotic effects attributed to this lipoprotein. Sphingosine-1-phosphate (S1P) and the acute phase protein serum amyloid A (SAA) have been identified as integral constituents of HDL particles. Evidence suggests that S1P and SAA levels within HDL particles may be affected by inflammation and oxidative stress, which are coexisting processes underlying ASCVD. Because SAA, an inflammation-related marker, and S1P, an anti-atherothrombotic marker, have relatively clear opposite characteristics among the HDL-associated proteins, the approach of assessing the two markers simultaneously may provide new insights in clinical practice (S1P/SAA Index). This review focuses on evidence in support of the concept that the S1P/SAA Index may affect the HDL atheroprotective properties and may, therefore represent a potential target for therapeutic interventions.
| INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. 1, 2 On the basis of 2012 mortality rate data, more than 48 000 people die of ASCVD each day, an average of one death every 1-2 seconds. 2 The causes of ASCVD are multifactorial, and may include factors related to lifestyles, age, male gender and other factors such as arterial hypertension, type 2 diabetes and dyslipidaemia. relationship between the levels of HDL-cholesterol and the presence or development of ASCVD. 4, 5 The incidence of ASCVD events in a normal population appears to be inversely related to the concentration of serum HDL-cholesterol, with low levels being associated with increased ASCVD risk. 6, 7 Based upon data from the Framingham Heart Study, the risk for ASCVD increases by about 25 percent for every 5 mg/dL (0.13 mmol/L) decrement in serum HDL-cholesterol below median values for men and women. 8 HDL-cholesterol levels are also predictive of coronary events in patients with known ASCVD.
Landmark studies, including the Framingham Heart Study 8 and the
Prospective Cardiovascular Munster (PROCAM)
, showed that low HDL-cholesterol levels are an independent risk factor for ASCVD and estimated that an increase of 1 mg/dL (0.026 mmol/L) in HDLcholesterol is associated with a 2%-3% of risk reduction. 8, 9 Further evidence comes from experimental models as atherosclerosis may be retarded or even reversed in transgenic mice expressing high levels of human apolipoprotein (apo) A-I, the constitutive and most abundant protein of HDL. 10 In addition, the infusion of reconstituted HDL particles was shown to reduce atherosclerotic coronary plaque volume in both experimental models and humans. 10 These observations have stimulated several laboratories and research groups worldwide to focus their research efforts on the development of therapies aiming at increasing HDL-cholesterol. Despite the above evidence in support of a potential benefit from raising HDL-cholesterol, accumulating evidence suggests that simply increasing the amount of circulating HDLcholesterol does not protect against ASCVD. 11, 12 This leads to the hypothesis that the HDL in some patients may be dysfunctional and its other properties and compositions like sphingosine-1-phosphate (S1P) and the acute phase protein serum amyloid A (SAA) might be more important than its cholesterol cargo. 13 This review focuses on evidence in support of the concept that compositional differences of S1P and SAA in the HDL-containing fraction of human plasma may provide important information on atherosclerotic cardiovascular risk and may represent a potential target for future therapeutic interventions. 18, 19 Since both niacin and CETP inhibitor trials were performed in patients receiving statin therapy thus raising the possibility that the potential beneficial effects of HDL-cholesterol elevation were pre-empted by lowering plasma LDL-cholesterol, recent results of other experimental approaches also undermine the contention that high HDL-cholesterol affords protection against ASCVD. 20 In the more recent REVEAL trial, the addition of the CETP inhibitor anacetrapib to intensive statin therapy resulted in a lower incidence of ASCVD events among patients with documented ASCVD, via a mechanism which may be independent of its HDL-C-raising pharmacological actions.
| HDL-CHOLESTEROL CONTENT: A POOR METRIC FOR ANTI-ATHERO-THROMBOTIC EFFECTS EXERTED BY HDL

17.
The issue of whether higher levels of HDL-cholesterol cause a lower risk of ASCVD was also addressed in a 2012 Mendelian randomization study, which evaluated the relationship between HDLcholesterol level and the risk of ASCVD. 21 The authors showed that common single-nucleotide polymorphisms (SNPs) that are exclusively associated with higher serum HDL-cholesterol levels are not usually associated with a decreased risk of myocardial infarction. In contrast, reduced risk of myocardial infarction was observed in carriers of SNPs that are associated with lower levels of LDL-cholesterol.
In summary, HDL-cholesterol content may, therefore be a poor metric for anti-athero-thrombotic effects exerted by HDL. 11, 12 When evaluating the studies looking at HDL-cholesterol as a potential cause of ASCVD, it should, therefore, be kept in mind that the cholesterol component is only one of many structural or functional components of the HDL particle, which in addition consist of several molecules of apoA-I, phosphatidylcholine molecules, minor proteins, diverse lipids species, and even microRNA [22] [23] [24] [25] and more knowledge about specific functions of these molecule is required and still need to be explored.
That is, if HDL-cholesterol is found not to be causally associated with ASCVD, it is possible that other components of HDL directly or indirectly contribute to the anti-athero-thrombotic potential of HDL, 20 as illustrated in Figure 1 .
| EFFECTS OF SPHINGOSINE-1-PHOSPHATE-RICH HDL IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Several studies [26] [27] [28] have demonstrated that HDL may serve as a carrier for S1P, a lysosphingolipid exerting its biological actions mainly via the binding to five G protein-coupled receptors, named S1P 1-5 .
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S1P has been shown to regulate several biological actions in a variety of different organ systems, including the cardiovascular system.
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Accumulating evidence suggests that S1P may mediate several actions of HDL including vasodilation, angiogenesis and endothelial barrier function, and protection against atherosclerosis and ischaemia/ reperfusion injury. 33, 34 In fact, decreased levels of S1P have been observed in cases of increased vascular permeability, such as sepsis. 35 Those who heavily engage in activities that are protective from cardiovascular pathology, such as exercise, have been shown to have increased levels of total plasma, and HDL-bound, S1P. 36 Indeed, a remarkable study by Deutschman and colleagues has established that S1P can be a greater predictor of CAD than conventional risk factors examined in practice today, including age, sex, hypertension, diabetes mellitus, family history etc. 37 Not only is S1P useful in predicting coronary artery stenosis, studies by Jing et al 38 have also demonstrated that HDL-S1P levels in patients with coronary artery in-stent restenosis (ISR) are significantly lower than patients without this form of disease recurrence, and that HDL-S1P can be considered a protective factor against ISR.
Interestingly, Sattler and colleagues found that plasma concentrations of S1P-rich HDL were lower whereas those of non-HDL-bound S1P were higher in subjects with myocardial infarction and stable ASCVD, when compared with healthy controls. 39 In addition, the authors found both parameters to mirror the clinical severity of ASCVD symptoms. 39 The concentration of non-HDL-bound plasma S1P increased significantly with increasing severity of symptoms whereas normalized plasma S1P-rich HDL levels were inversely correlated with the severity of symptoms. 39 Another study evaluated how S1P
concentration in an HDL-containing fraction of human serum correlate with occurrence of ASCVD in 204 subjects selected from the Copenhagen City Heart Study (CCHS) cohort. 40 The study reported that levels of S1P-rich HDL were inversely related to the occurrence of ASCVD, but no significant correlation was found between free S1P levels in total serum and the occurrence of ASCVD. 40 Intriguingly, this inverse relationship was independent of HDL-cholesterol levels upon subject stratification for high and low serum HDL-cholesterol, 40 this is despite the fact that HDL is a key carrier of S1P in plasma. 41 The authors also found that in individuals free of ASCVD, the S1P-rich HDL levels were higher than that of ASCVD-affected individuals, suggesting that the mechanism regulating the partitioning of S1P to HDL vs other lipoproteins or albumin may act differently between ASCVD and non-ASCVD individuals. 40 With regard to the non-ASCVD subjects, those with type 2 diabetes may also exhibit reduced levels of S1P in their HDL particles, and this may explain, at least in part, the observed elevated ASCVD risk in this patient population. In fact, Brinck and colleagues 42 demonstrated that glycation of HDL can lead to a decrease in S1P content as well as a reduced binding to cardiomyocytes. In addition, the authors found an inverse relationship between HbA1c and S1P levels in diabetic patients.
The above observations suggest that the structural or functional components of the HDL particles may be dynamic: some components can dissociate from, and associate back with HDL particles under different pathological conditions. 43 These structural alterations in the composition of HDL particles may affect significantly the antiatherothrombotic properties of HDL and convert these lipoproteins into pro-atherothrombotic particles. 44 In fact, Sattler and colleagues demonstrated that in patients with ASCVD, the anti-atherothrombotic actions of HDL are lost with a loss of S1P. 
| EFFECTS OF SERUM AMYLOID A-RICH HDL IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Serum amyloid A is an acute phase protein produced primarily by hepatocytes, but also by adipocytes, macrophages and enterocytes.
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SAA plays a vital role in immunomodulation, stimulating neutrophils and mast cells, as well as being involved in the production of cytokines, 46 some of which potentially promoting endothelial dysfunction, monocytes infiltration, possibly insulin resistance, as illustrated in Figure 2B . 47 In addition, SAA is also a chemotactic ligand for FPRL1, a phagocyte receptor which also shows affinity for the potent chemotactic factor, fMLP. 48 The activation of FPRL1 may facilitate chemotactic migration as well as promoting reactive oxygen species production, which ultimately may lead to the development and/or progression of ASCVD.
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Numerous studies have reported increased levels of serum SAA in patients with ASCVD, including heart failure and coronary artery disease. 50, 51 Patients with ASCVD have been shown to have a 2-fold increase in serum SAA levels when compared to controls. 52 Not only is this phenomenon observed in patients with ASCVD, but also in those who exhibit cardiovascular risk factors, such as diabetes mellitus, smoking, renal impairment and advancing age. Evidence suggests that in the presence of SAA, HDL particles may become dysfunctional. 59, 61 In fact, during an acute phase response, SAA may accumulate into HDL particles and disrupts their anti-atherothrombotic actions including the cholesterol efflux capacity, the anti-oxidative and anti-inflammatory properties, 44, 62, 63 as illustrated in Figure 2 .
Consistently, HDL supplemented with SAA inhibits endothelial NO production, increases endothelial production of ROS, as well as disinhibiting VCAM-1 expression and subsequently increasing mononuclear cell adhesion to TNF-α treated endothelial cells. 52 ApoA-I is a negative acute phase protein and is thought to be a constituent of HDL which is involved in exhibiting the anti-inflammatory properties of HDL, by stemming the release of cytokines. 46 In an acute phase response, however, it has been observed to be replaced by the proatherogenic SAA. 46, 59 An additional mechanism by which SAA may lead to dysfunctional HDL is the impairment of reverse cholesterol transport. 54 HDL cell-cholesterol efflux capacity (CEC) has been inversely linked to ASCVD. [64] [65] [66] The primary methods of cell-cholesterol efflux are via ABCA1 and scavenger receptor class B type I (SR-BI).
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Studying the activity of these has allowed for a better understanding of cholesterol transport. In fact, deletions of SR-B1 have been shown to both increase HDL and accelerate atherosclerosis. 
| CONCLUSION AND FUTURE PERSPECTIVES
In summary, the structural or functional components of HDL particles may be important in the pathogenesis and progression of ASCVD because of the different, even opposite effects that HDL particles may exert on the cardiovascular system dependent on its S1P/SAA ratio cargo. There is therefore an urgent and unmet need to investigate the levels of S1P/SAA ratio in HDL particles from different populations, particularly those with ASCVD. Such a study would, not only clarify whether changes in S1P/SAA ratio may explain the commonly observed HDL dysfunction, which is typical in patients with ASCVD; but would also elucidate whether S1P/SAA ratio may serve as a potential diagnostic and therapeutic targets for the treatment and prevention of ASCVD.
